Research areas
Missouri Surgeons Separate Twins Conjoined at Head
Surgeons at a Missouri children's hospital successfully separated infant twin sisters born conjoined at the head earlier this year, according to a hospital
Latest Medical Research news
The system
Novo Nordisk partners with Anthropic to accelerate drug
Novo Nordisk has entered a collaboration with AI company Anthropic to speed up drug discovery and development, with an initial project testing the Claude
Research areas
FDA launches pilot to accelerate phase 1
The FDA has opened a pilot program pairing drug sponsors with qualified research institutions to expedite IND reviews, aiming to cut phase 1 trial
Clinical trials
EVOKE-03 Trial: Sacituzumab Fails to Boost Survival
The phase III EVOKE-03 trial found adding the antibody-drug conjugate sacituzumab govitecan to pembrolizumab immunotherapy did not significantly improve
Clinical trials
Cullinan and Taiho drug extends lung cancer
In a phase 3 trial, adding zipalertinib to chemotherapy improved median progression-free survival to 14.5 months, a six-month gain over chemo alone, for
Explore topics
Monitored sourcesMedPage TodayBioPharma DiveFierce BiotechNature MedicineJAMA NetworkThe Lancetfda.gov
The index
Clinical trials
GSK's risvutatug rezetecan shows 18.5-month
GSK and Hansoh Pharma's antibody-drug conjugate risvutatug rezetecan achieved a median overall survival of 18.5 months in a phase 3 trial for relapsed
Regulation
FDA delays Exelixis' zanzalintinib decision to March 2027
The FDA has postponed its approval decision for Exelixis' oral kinase inhibitor zanzalintinib in metastatic colorectal cancer, requesting updated data and
The system
IL-33 Inhibitor Tozorakimab Cuts COPD Exacerbations
The biologic drug tozorakimab, which targets interleukin-33, significantly reduced the rate of moderate and severe exacerbations in patients with COPD
Research areas
Kura spins out Caspian to test menin
Kura Oncology has spun out a new biotech startup, Caspian Therapeutics, to develop menin inhibitor drugs for diabetes and cardiometabolic diseases.
Research areas
Kura spins out Caspian with $50M to test
Kura Oncology has created spinout Caspian Therapeutics, backed by $50 million from investors including Eli Lilly, to advance menin inhibitor KO-7246 for
Evidence
GLP-1 Drugs Linked to Fewer Asthma, COPD Attacks in Study
A large real-world study presented at the ERS Congress found patients with asthma or COPD who started a GLP-1 drug had a 14% lower risk of severe
Regulation
FDA approves AstraZeneca's Etcamah for ctDNA-guided breast
The FDA granted accelerated approval to AstraZeneca's camizestrant (Etcamah) for HR-positive, HER2-negative breast cancer patients with an ESR1 mutation
Clinical trials
Roivant's lung hypertension drug hits Phase 2 goals
Roivant's mosliciguat reduced a key lung pressure measure by 56% in a Phase 2 trial for PH-ILD, with analysts citing multi-billion dollar potential.
The system
Moonwalk Biosciences pivots to RNAi obesity drugs with $70M
Moonwalk Biosciences has raised $70 million in Series B funding to advance a pipeline of RNA interference drugs for obesity, pivoting from its original
Regulation
Ketamine Outperforms Midazolam in Bipolar Depression Trial
A small trial found adjunctive ketamine was more effective than midazolam for treatment-resistant bipolar depression.
Profiles
Data and guides
Also filed
Evidence
ADARx files for IPO to fund three
ADARx Pharmaceuticals has filed for an initial public offering to raise funds for advancing its pipeline of siRNA therapies, including mid- and late-stage
Research areas
Novartis Phase 3 Trial Fails for Lp(a) Drug Pelacarsen
Novartis's pelacarsen, an antisense drug developed with Ionis to lower lipoprotein(a), did not reduce major cardiovascular events in high-risk patients in
The system
AI Tool Prof. Valmed Speeds Up Rheumatology Diagnosis
A randomized trial found the AI system Prof. Valmed cut diagnosis time by more than half compared to physicians working alone, but did not improve
Clinical trials
Novo Nordisk ends two more phase 3 trials
Novo Nordisk has discontinued two late-stage heart failure trials for its drug ziltivekimab after a data review, leaving one remaining study to determine
Clinical trials
Akeso's Ivonescimab Shows Lung Cancer Survival Edge
Akeso and Summit Therapeutics report their bispecific antibody ivonescimab helped lung cancer patients live longer than those on Merck's Keytruda in a
The system
Induced Proximity Therapies Gain Ground After First PROTAC
The first FDA-approved PROTAC drug for breast cancer has validated a new class of medicines that work by bringing proteins together.
Regulation
Compounded GLP-1 Drugs Persist Post-Shortage, Study Finds
A secret shopper study in JAMA Health Forum reveals compounded GLP-1 drugs for weight loss remain widely available in West Virginia and Oklahoma despite
Clinical trials
Invivyd chairman becomes CEO ahead of COVID
Infectious disease biotech Invivyd has appointed board chairman Marc Elia as its new CEO, with the leadership change coming ahead of key phase 3 trial
Clinical trials
Novartis, Ionis heart drug fails in major Phase 3 trial
Novartis and Ionis Pharmaceuticals' experimental drug pelacarsen failed to reduce heart attacks, strokes or death in a Phase 3 study of over 8,000 people.
Regulation
Ionis' Zanvastro Wins First FDA Approval for Alexander
The FDA has approved Ionis Pharmaceuticals' Zanvastro, the first treatment for the rare neurological disorder Alexander disease.
Research areas
Lancet Series calls for reimagined maternal
A new Lancet Series argues that cardiovascular care in pregnancy must shift from reacting to crises to anticipating and managing long-term risk, stating up
Regulation
FDA Grants Accelerated Approval to AstraZeneca's Etcamah
The FDA has granted accelerated approval to AstraZeneca's Etcamah for HR-positive, HER2-negative advanced breast cancer with ESR1 mutations, based on a
Browse sections
Common questions
What is Bench to Bed for?
Reporting studies and trials as evidence: what was actually tested, in whom, and what it showed. Research areas groups the science, Clinical trials follows the pipeline, Regulation covers approvals, Evidence deals with how strong a finding is, and The system covers funding and publication.
Does a study reported here mean a treatment works?
No. Most published findings are early, small or in animals, and the piece says which. Nothing on this site is medical advice, and no reader should change anything about their treatment because of a summary.
How do you handle preprints and press releases?
They are reported as what they are. A piece names whether its source was a peer-reviewed paper, a preprint, a conference abstract or an institutional release, and links to it, because the type of source changes how much weight it carries.
Is the writing done by a person?
Nobody is bylined and nobody is presented as a researcher or a physician. Pieces are written with automated assistance from the source material, crediting the publication or journal instead, as Sources and methods explains.
How do I flag a factual error?
The Corrections page asks for the article address and the specific claim you believe is wrong. Corrections are made on the article with a dated note at the foot, and substantive ones are listed.
Can I subscribe by RSS?
Yes, at /feed.xml, carrying every piece as it publishes. It needs no account and no key.